or Connect
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CVM - CEL-SCI CORPORATION
New Posts  All Forums:Forum Nav:

CVM - CEL-SCI CORPORATION - Page 568

post #11341 of 11480
CEL-SCI Announces Presentation by Its Chief Scientific Officer at "Targeted Cancer Therapies" Conference in London Today
Last update: 5/27/2010 9:15:00 AM
VIENNA, Va., May 27, 2010 (BUSINESS WIRE) -- CEL-SCI Corporation (CVM) announced today that Dr. Eyal Talor, the Company's Chief Scientific Officer, will be giving a featured presentation titled "Latest Clinical Results using Multikine(R) Immunotherapy for Cancer" today at 3:05 pm London time at the "Targeted Cancer Therapies" conference in London, UK. The presentation will highlight Multikine's role as a potential treatment for head and neck cancer, and will include a discussion of Phase II clinical results and details on the Company's upcoming Phase III pivotal study.
This conference gathers the world's leading experts in oncology research and development to focus on innovative development of cancer drugs.
About Multikine
Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.
Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received surgery, chemotherapy and/or radiation therapy, which can limit their effectiveness.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S.(TM) technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is currently being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit .
SOURCE: CEL-SCI Corporation

CEL-SCI Corporation Gavin de Windt, 703-506-9460

Copyright Business Wire 2010
post #11342 of 11480
Why you don't think this stock will go back up??
post #11343 of 11480
i dont like where its at this time, may be in two months. it reminds me of a tail end dump thou. lol
post #11344 of 11480
http://www.cel-sci.com/video4REVIEW.html

How old is this video? 2007? I hope not, i think it was just last month?
post #11345 of 11480



Can't wait to make all my email subscribers some biggg moneY!!!!


:

BOO YAH BOO YAH

:

I'm poor, not making any money you guys just trying to help you!


Sorry.... I couldn't resist when I saw EEE and RZ are too of tommy's picks that have recently been deleted from the Russell index. ROFL
post #11346 of 11480
So what will happen to this now??
post #11347 of 11480
Quote:
Originally Posted by Every1bets View Post
So what will happen to this now??
Go find TG in IHUB, ask him to come back here with a different username, and pump this one up again to 2 bucks
post #11348 of 11480
Quote:
Originally Posted by coldwind View Post
Go find TG in IHUB, ask him to come back here with a different username, and pump this one up again to 2 bucks
That would be great,,I can use the the xtra cash
post #11349 of 11480
Quote:
Originally Posted by Every1bets View Post
So what will happen to this now??

To answer your question,,the only thing that would make this go again would be a Good PR and the status and FDA approval of their head and neck cancer drugs until then this will sit at this level.
post #11350 of 11480
Your talking a FEW YEARS maybe more


In @ .40 =)
post #11351 of 11480
Nice! Finally up .10 from when you got it
post #11352 of 11480

Coming back from the dead!!!

CEL-SCI Successfully Produces and Fills Multikine in New Manufacturing Facility


2010-08-04 09:45 ET - News Release

Company Completes Key Step in Preparation for Pivotal Phase III Trial

Company Website: http://www.cel-sci.com
VIENNA, Va. -- (Business Wire)
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.
The drug was filled in CEL-SCI’s state-of-the-art "Cold-Fill" manufacturing facility. The Company completed this test in order to ensure that it is able to produce significant quantities of Multikine to support the 880 patient clinical trial which is expected to commence prior to the end of the year. CEL-SCI's manufacturing facility, located outside of Baltimore, has been designed to fill biologics such as Multikine in true cold conditions (4 degrees Centigrade) which prevents/minimizes the loss of biological activity.
"Over the past few months, we have been highly focused on staffing and testing the facility in order to ensure that we have the equipment, resources and personnel to deliver Multikine to patients in the Phase III trial," said Geert Kersten, CEL-SCI's Chief Executive Officer. "We recognize that in a trial of this scale involving a biologic there are many precautions that we need to take, and we have made excellent progress in completing these tasks so we can begin the trial later this year. With a strong balance sheet, the new manufacturing facility, a global CRO in place and having Phase III partners Teva Pharmaceuticals and Orient Europharma, we are well positioned to take Multikine through this pivotal trial. We believe that Multikine represents a paradigm shift in the way cancer patients are treated."
In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to eliminate the tumors in 12% of the patients after only three weeks of treatment. Follow-up showed an improvement in the survival rate of those patients treated with Multikine of 33% at a median of three and a half years following surgery. Results of the trial also showed that the treatment regimen killed, on average, about half of the cancer cells before the start of standard therapy like surgery, radiation and chemotherapy. The U.S. Food and Drug Administration gave the go-ahead for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
CEL-SCI is also engaged in multiple other activities related to the start its Phase III clinical trial in 9 countries around the world. The trial is expected to be the largest head and neck cancer clinical study ever conducted, and is the first Phase III study in the world in which immunotherapy is given to patients first, prior to receiving any treatment for cancer, including surgery, radiation and/or chemotherapy. This should be the optimal time to stimulate an immune response against the tumor as the immune system has not yet been weakened by the conventional cancer therapies
post #11353 of 11480
Glad im not in this stock anymore
post #11354 of 11480
It's about time. Now, when do they start leasing out some space in the facility like they stated. I am in this 2K shares just put back with years to sit. I hope they are sucessful one day.
post #11355 of 11480
i hope they are successful one day too so i can sell this POS haha
post #11356 of 11480
Here we go again with "The Facility"
post #11357 of 11480
VIENNA, Va.--(Business Wire)--
CEL-SCI Corporation (NYSE AMEX: CVM) announced today it has received approval
from the North Mississippi Health Services ("North Mississippi") Institutional
Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical
trial of Multikine�, the Company`s flagship immunotherapy developed as a
first-line standard of care in treating head and neck cancer. An IRB is a group
formally designated by an institution to review and monitor research involving
human subjects and to ensure protection of their rights and welfare.
CEL-SCI`s Phase III clinical trial is an open-label, randomized, multi-center
study designed to determine if Multikine administered prior to current standard
of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo
radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the
Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased
overall rate of survival versus the subjects treated with standard of care only.
North Mississippi is the first site in the United States to approve enrollment
of subjects. CEL-SCI`s trial will be conducted in nine countries and is expected
to be the largest clinical study of head and neck cancer ever conducted. It will
also be the first trial in which immunotherapy will be administered before any
other traditional means of care are attempted. CEL-SCI plans to announce
additional site approvals and country approvals as they become known.
Phase II clinical trials of Multikine demonstrated the product was safe and
well-tolerated and eliminated tumors in 12% of the subjects less than a month
into treatment. The Multikine treatment regimen was also shown to kill, on
average, about half of the cancer cells in the subjects` tumors before the start
of standard therapy. Follow-up studies of subjects enrolled in Phase II trials
showed a 33% improvement in the survival rate of those treated with Multikine at
a median of three and a half years following surgery. The U.S. Food and Drug
Administration gave clearance for a Phase III clinical trial and granted orphan
drug status to Multikine in the neoadjuvant therapy of patients with squamous
cell carcinoma of the head and neck.
About North Mississippi Health Services
North Mississippi Health Services (NMHS) is a diversified regional health care
organization, which serves 24 counties in north Mississippi and northwest
Alabama from headquarters in Tupelo, Mississippi. The NMHS organization covers a
broad range of acute diagnostic and therapeutic services, offered through North
Mississippi Medical Center in Tupelo; a community hospital system with locations
in Eupora, Iuka, Pontotoc, West Point, Miss. and Hamilton, Alabama, North
Mississippi Medical Clinics, a regional network of more than 30 primary and
specialty clinics; and nursing homes. NMHS has an IRB that meets monthly. The
NMHS IRB members include doctors, nurses, pharmacists, social workers, a lawyer,
risk manager, and community members. This group reviews the science and ethics
of the research. Their objective is to assess the risks and benefits to subjects
involved in the study. The NMHS IRB has the authority to approve, require
modification to, or disapprove all research activities that involve an NMHS
investigator, facility, or patient group. Following initial approval, the IRB
conducts periodic reviews of such research. In most instances, in order to
approve research, an IRB must determine that specified criteria have been
satisfied. Among these criteria, an IRB must determine that, when appropriate,
the research protocol includes "adequate provisions to protect the privacy of
subjects and to maintain the confidentiality of data."
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its
lead product is Multikine. In Phase II clinical trials Multikine was shown to be
safe and well-tolerated, and to improve the patients' overall survival by 33
percent at a median of three and a half years following surgery. A pivotal Phase
III clinical trial with Multikine in head and neck cancer is expected to start
in the second half of 2010.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1
hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using
its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing
regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI
scientists are very concerned about the creation of a new more virulent hybrid
virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This
investigational treatment is being tested in a clinical study at Johns Hopkins
University. The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
For more information, please visit www.cel-sci.com.

CEL-SCI Corporation
Gavin de Windt, 703-506-9460
Copyright Business Wire 2010
post #11358 of 11480
LOL.
post #11359 of 11480
where is TommyGun and his cheerleaders?
post #11360 of 11480
Quote:
Originally Posted by coldwind View Post
where is TommyGun and his cheerleaders?
Looks like your here.
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CVM - CEL-SCI CORPORATION